Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin for Prevention of Acute Kidney Injury in Patients With Type 2 Diabetes Mellitus Undergoing Extracorporeal On-pump CABG: The POST-CABGDM Trial

NCT04523064 is registered in ClinicalTrials.gov with University of Sao Paulo General Hospital as lead sponsor.

NCT NCT04523064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04523064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin for Prevention of Acute Kidney Injury in Patients With Type 2 Diabetes Mellitus Undergoing Extracorporeal On-pump CABG: The POST-CABGDM Trial
Lead sponsor
University of Sao Paulo General Hospital
Phase
Phase 4
Overall status
Completed
Start date
September 22, 2020
Completion date
January 30, 2024
Enrollment
155 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, coronary artery bypass surgery, coronary artery disease, diabetes mellitus, type 2